February 4, 2022
Takeda Pharmaceutical notched up double-digit earnings growth in the first three quarters of FY2021, registering higher revenue in all its focus therapeutic areas, with its top product Entyvio (vedolizumab) expanding over 20%. In April-December, the Japanese drug juggernaut posted group...read more